The technique of attaching the polymer polyethylene glycol (PEG), or PEGylation, has
brought more than ten protein drugs into market. The surface conjugation of PEG on proteins …

Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs
in children between 2 and 10 years of age. L-asparaginase is an integral component of …

Simple Summary L-asparaginase (L-ASNase) therapy is key for achieving the very high cure
rate of pediatric acute lymphoblastic leukemia (ALL), yet its use is mostly confined to this …

Pediatric Acute Lymphoblastic Leukemia (ALL) cure rates have improved exponentially over
the past five decades with now over 90% of children achieving long-term survival. A direct …

L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia.
However, asparaginase-related complications, including the development of hypersensitivity …

Abstract l-asparaginase is a critical part of the treatment of acute lymphoblastic leukaemia in
children and adolescents, and has contributed to the improvement in patient outcomes over …

Asparaginase is an integral component of multiagent chemotherapy regimens for the
treatment of acute lymphoblastic leukemia (ALL). Adequate asparagine depletion is …

During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be
affected by severe acute side effects, the most common being opportunistic infections …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Bacterial L‐
asparaginase has played an important role in ALL treatment for several decades; however …

Background Asparaginase is a critical component of lymphoblastic leukemia therapy, with
intravenous pegaspargase (PEG) as the current standard product. Acute adverse events …